I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
Hillhouse Capital – which led the company’s last private funding round before its IPO – also led the private placement, with Singapore’s GIC Private coming in as a significant investor. Other backers...
An investment firm with ties to renowned Japanese activist investor Yoshiaki Murakami is challenging The Carlyle Group’s JPY37 ($355 million) bid for Japan Asia Group by launching a tender offer of its own.
The proposal to place a 0% tax on carried interest has been welcomed in Hong Kong, but PE industry participants are quietly looking to Hong Kong Monetary Authority to ensure balanced execution of the policy
Technology and healthcare-focused Oceanpine Capital sees the large GP commitment to its fund and the network of its founder as key differentiators in a competitive Chinese market
Chinese industrial robot manufacturer Jaka Robotics has raised RMB300m ($46m) in Series C funding led by CPE and State Development and Investment Corporation (SDIC).